

chain nodes :

7 8 9 10 11 12 13 17

ring nodes :

1 2 3 4 5 6

chain bonds :

2-17 4-7 5-8 6-9 9-10 9-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 2-17 3-4 4-5 4-7 5-6 5-8 9-10 9-11

exact bonds :

6-9

isolated ring systems :

containing 1 :

G1:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:CLASS11:CLASS12:Atom  
13:CLASS17:CLASS

Generic attributes :



12:

Saturation : Unsaturated

13:  
Saturation : Unsaturated

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10500971.str



chain nodes :  
 7 8 9 10 11 12 13 17  
 ring nodes :  
 1 2 3 4 5 6  
 chain bonds :  
 2-17 4-7 5-8 6-9 9-10 9-11  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 exact/norm bonds :  
 1-2 1-6 2-3 2-17 3-4 4-5 4-7 5-6 5-8 9-10 9-11  
 exact bonds :  
 6-9  
 isolated ring systems :  
 containing 1 :

G1:[\*1],[\*2]

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
 11:CLASS 12:Atom 13:CLASS 17:CLASS  
 Generic attributes :  
 12:  
 Saturation : Unsaturated  
 13:  
 Saturation : Unsaturated


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

Cy<sup>1</sup>



Ak<sup>2</sup>

G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:20:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 179 TO ITERATE

100.0% PROCESSED 179 ITERATIONS

13 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 2778 TO 4382

PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 14:22:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3612 TO ITERATE

100.0% PROCESSED 3612 ITERATIONS

305 ANSWERS

SEARCH TIME: 00.00.01

L3 305 SEA SSS FUL L1

=> => s l3

L4 24 L3

=> d l4 1-24 bib,ab,hitstr

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:406715 CAPLUS

DN 144:468112

TI Suzuki coupling at the 2-position of densely functionalized pyrimidones

AU Colarusso, Stefania; Girardin, Melina; Conte, Immacolata; Narjes, Frank

CS IRBM-Merck Research Laboratories Rome, Rome, 00040, Italy

SO Synthesis (2006), (8), 1343-1350

CODEN: SYNTBF; ISSN: 0039-7881

PB Georg Thieme Verlag

DT Journal

LA English

AB A variety of Et 1-substituted 2-aryl-5-ethoxy-6-oxo-1,6-dihydropyrimidine-4-carboxylates were synthesized by efficient thermal or microwave-promoted Suzuki coupling of 2-chloro-N1-substituted precursors.

IT 572917-63-6P 886221-52-9P 886221-53-0P

886221-54-1P 886221-56-3P 886221-57-4P

886221-58-5P 886221-59-6P 886221-60-9P

886221-61-0P 886221-62-1P 886221-63-2P

886221-64-3P 886221-65-4P 886221-66-5P

886221-67-6P 886221-68-7P 886221-69-8P


886221-70-1P 886221-71-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of 2-aryldihydropyrimidinecarboxylates via palladium catalyzed thermal or microwave-promoted Suzuki coupling of chloro-substituted pyrimidinone intermediate with arylboronic acids)


RN 572917-63-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-6-oxo-2-(3-thienyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-52-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-2-(3-methoxyphenyl)-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-53-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-6-oxo-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-54-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(4-acetylphenyl)-5-ethoxy-1,6-dihydro-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-56-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-6-oxo-2-(2-thienyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-57-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-2-(4-methoxyphenyl)-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-58-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-2-(2-methoxyphenyl)-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-59-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-2-(1-naphthalenyl)-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-60-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-2-(2-methylphenyl)-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-61-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,6-dimethylphenyl)-5-ethoxy-1,6-dihydro-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 886221-62-1 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-2-(2-naphthalenyl)-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 886221-63-2 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-2-(4-formylphenyl)-1,6-dihydro-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)






RN 886221-64-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(4-ethenylphenyl)-5-ethoxy-1,6-dihydro-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-65-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-6-oxo-2-phenyl-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-66-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-2-(2-methylphenyl)-6-oxo-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-67-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-6-oxo-1-(phenylmethyl)-2-(3-thienyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-68-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-6-oxo-1,2-diphenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-69-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-2-(2-methylphenyl)-6-oxo-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-70-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-2-(4-methoxyphenyl)-6-oxo-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 886221-71-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,6-dimethylphenyl)-5-ethoxy-1,6-dihydro-6-oxo-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:83149 CAPLUS  
 DN 144:285632  
 TI 2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of the  
 Hepatitis C Virus NS5B Polymerase: Discovery, SAR, Modeling, and  
 Mutagenesis  
 AU Koch, Uwe; Attenni, Barbara; Malancona, Savina; Colarusso, Stefania;  
 Conte, Immacolata; Di Filippo, Marcello; Harper, Steven; Pacini, Barbara;  
 Giomini, Claudia; Thomas, Steven; Incitti, Ilario; Tomei, Licia; De  
 Francesco, Raffaele; Altamura, Sergio; Matassa, Victor G.; Narjes, Frank  
 CS Istituto Di Ricerche Di Biologia Molecolare, P. Angeletti S.p.A. (Merck  
 Research Laboratories), Pomezia, 00040, Italy  
 SO Journal of Medicinal Chemistry (2006), 49(5), 1693-1705  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB Infections caused by hepatitis C virus (HCV) are a significant world  
 health problem for which novel therapies are in urgent demand. The  
 polymerase of HCV is responsible for the replication of viral RNA. The  
 authors recently disclosed dihydroxypyrimidine carboxylates as novel,  
 reversible inhibitors of the HCV NS5B polymerase. This series was further  
 developed into 5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylic acids  
 such as (I) (EC50 9.3  $\mu$ M), which now show activity in the cell-based  
 HCV replication assay. The structure-activity relation of these  
 inhibitors is discussed in the context of their physicochem. properties  
 and of the polymerase crystal structure. We also report the results of  
 mutagenesis expts. which support the proposed binding model, which  
 involves pyrophosphate-like chelation of the active site Mg ions.  
 IT 391680-80-1P 572916-89-3P 572916-90-6P  
 878649-60-6P 878649-62-8P 878649-63-9P  
 878649-64-0P 878649-65-1P 878649-68-4P  
 878649-69-5P 878649-70-8P 878649-71-9P  
 878649-72-0P 878649-73-1P 878649-74-2P  
 878649-75-3P 878649-76-4P 878649-77-5P  
 878649-78-6P 878649-79-7P 878649-80-0P  
 878649-81-1P 878649-82-2P 878649-83-3P  
 878649-84-4P 878649-85-5P 878649-86-6P  
 878649-87-7P 878649-88-8P 878649-89-9P  
 878649-90-2P 878649-91-3P 878649-92-4P  
 878649-93-5P 878649-94-6P 878649-95-7P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)  
 (preparation and structure activity relations of  
 (thienyl)dihydroxycarboxypyrimidines as inhibitors of hepatitis C virus  
 NS5B polymerase)  
 RN 391680-80-1 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)methyl]amino]carbonyl  
 amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 572916-89-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thiazolyl)-  
(9CI) (CA INDEX NAME)




RN 572916-90-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-(3-nitro-2-thienyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-60-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2-furanyl)-1,6-dihydro-5-hydroxy-6-oxo-  
(9CI) (CA INDEX NAME)




RN 878649-62-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[1-(phenylmethyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 878649-63-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(1H-imidazol-2-yl)-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-64-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-pyrazinyl- (9CI) (CA INDEX NAME)




RN 878649-65-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-benzo[b]thien-2-yl-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-68-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(5-methyl-2-thienyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-69-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-methyl-2-thienyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-70-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(5-nitro-2-thienyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-71-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(4-nitro-2-thienyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-72-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-nitro-2-thienyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 878649-73-1 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[4-[(2-thienylcarbonyl)amino]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 878649-74-2 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(3-amino-2-thienyl)-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)






RN 878649-75-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-  
[[[(phenylmethyl)amino]carbonyl]amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 878649-76-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-  
[[[(phenylmethoxy)carbonyl]amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 878649-77-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[(2-  
naphthalenylsulfonyl)amino]-2-thienyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-78-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(phenylacetyl)amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 878649-79-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[[ (phenylamino)carbonyl]amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 878649-80-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-(benzoylamino)-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-81-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[[[2-phenylethyl)amino]carbonyl]amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 878649-82-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[[[2-phenylethoxy)carbonyl]amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 878649-83-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(1-oxo-3-phenylpropyl)amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 878649-84-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)methoxy]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 878649-85-5 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)acetyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 878649-86-6 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[[(2-chloro-6-methylphenyl)methyl]amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-

6-oxo- (9CI) (CA INDEX NAME)




RN 878649-87-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2,6-dichlorophenyl)methoxy]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-88-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[(1H-indol-3-ylacetyl)amino]-2-thienyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-89-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(benzo[b]thien-3-ylmethyl)amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 878649-90-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[(benzo[b]thien-3-ylacetyl)amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 878649-91-3 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[[[(1-naphthalenylmethoxy)carbonyl]amino]-2-thienyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 878649-92-4 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[[[(2-phenyl-

1H-indol-3-yl)acetyl]amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 878649-93-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-nitro-2-thienyl)-6-oxo-1-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 878649-94-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-nitro-2-thienyl)-6-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 878649-95-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




IT 391680-79-8  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (preparation and structure activity relations of  
 (thienyl)dihydroxycarboxypyrimidines as inhibitors of hepatitis C virus  
 NS5B polymerase)  
 RN 391680-79-8 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-  
 (9CI) (CA INDEX NAME)




IT 391680-92-5P 391680-96-9P 391680-97-0P  
 572916-82-6P 572916-83-7P 878650-16-9P  
 878650-17-0P 878650-18-1P 878650-19-2P  
 878650-20-5P 878650-21-6P 878650-22-7P  
 878650-23-8P 878650-24-9P 878650-25-0P  
 878650-26-1P 878650-27-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and structure activity relations of  
 (thienyl)dihydroxycarboxypyrimidines as inhibitors of hepatitis C virus  
 NS5B polymerase)  
 RN 391680-92-5 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-,  
 methyl ester (9CI) (CA INDEX NAME)






RN 391680-96-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-97-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-amino-2-thienyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 572916-82-6 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-2-(3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 572916-83-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-

methyl-2-(3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-16-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2-furanyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-17-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thiazolyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-18-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[1-(phenylmethyl)-1H-imidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-19-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-pyrazinyl-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-20-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-benzo[b]thien-2-yl-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 878650-21-6 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(5-methyl-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 878650-22-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-methyl-2-thienyl)-

6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-23-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(5-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-24-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(4-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-25-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-amino-2-thienyl)-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-26-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-2-(3-nitro-2-thienyl)-6-oxo-1-(2-propenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 878650-27-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-2-(3-nitro-2-thienyl)-6-oxo-1-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



IT 878650-28-3P 878650-29-4P 878650-30-7P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and structure activity relations of

(thienyl)dihydroxycarboxypyrimidines as inhibitors of hepatitis C virus NS5B polymerase)

RN 878650-28-3 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-6-methoxy-2-(3-nitro-2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 878650-29-4 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-2-(3-nitro-2-

thienyl)-6-(2-propenyloxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 878650-30-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-2-(3-nitro-2-thienyl)-6-(phenylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)




RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:81621 CAPLUS  
 DN 144:274229  
 TI Efficient synthesis of functionalized pyrimidones via microwave-accelerated rearrangement reaction  
 AU Zhong, Yong-Li; Zhou, Hua; Gauthier, Donald R.; Askin, David  
 CS Department of Process Research, Merck & Co., Inc., Rahway, NJ, 07065, USA  
 SO Tetrahedron Letters (2006), 47(8), 1315-1317  
 CODEN: TELEAY; ISSN: 0040-4039  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 144:274229  
 AB An efficient synthesis of functionalized pyrimidones via microwave-accelerated rearrangement reaction of amidoxime DMAD adducts is described. In most cases, the pyrimidone formation was furnished in reasonable yield after 2 min of microwave irradiation  
 IT 62222-36-0P 849475-89-4P 878158-13-5P  
 878158-14-6P 878158-15-7P 878158-16-8P  
 878158-17-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of pyrimidones via microwave-accelerated rearrangement of amidoxime acetylenedicarboxylate adducts)  
 RN 62222-36-0 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 849475-89-4 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 878158-13-5 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 2-(4-fluorophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 878158-14-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[4-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 878158-15-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[4-(trifluoromethoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 878158-16-8 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 878158-17-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)





RE.CNT 25      THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1242799 CAPLUS  
 DN 144:6805  
 TI Preparation of hydroxypyrimidinonecarboxamides as HIV integrase inhibitors  
 IN Naidu, B. Narasimhulu; Sorenson, Margaret E.  
 PA Bristol-Myers Squibb Company, USA  
 SO U.S. Pat. Appl. Publ., 34 pp.  
 CODEN: USXXCO.

DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005261322	A1	20051124	US 2005-127878	20050512
	US 7115601	B2	20061003		
	WO 2005115398	A2	20051208	WO 2005-US16976	20050513
	WO 2005115398	A3	20060420		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-572048P P 20040518

OS MARPAT 144:6805

AB Title compds. I [R1 = H, alkenyl, alkoxyalkyl, alkyl, and arylalkyl; R2 = 3-8 membered (un)saturated ring containing 1-3 heteroatoms, wherein said ring is

attached to the parent compound through one of its heteroatoms, and wherein said ring is substituted by a 3-10 membered (un)substituted monocyclic or bicyclic spirocycle containing 0-3 heteroatoms; R3 and R4 independently = H, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl], and their pharmaceutically acceptable salts, are prepared and disclosed as HIV integrase inhibitors. Thus, e.g., II was prepared by reaction of 2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-4-pyrimidinecarboxylic acid Et ester (multistep preparation given) with 4-fluorobenzylamine. In in-vitro assays to determine activity against HIV-integrase, select I were found to have IC50's of between ~0.01 and ~0.2  $\mu$ M. Also disclosed are pharmaceutical compns. comprising the compds., and methods of using the compds. The compds. are useful for treating HIV infection and AIDS.


IT 870082-23-8P 870082-24-9P 870082-36-3P  
 870082-37-4P 870082-38-5P 870082-39-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of hydroxypyrimidinonecarboxamides as HIV integrase inhibitors)


RN 870082-23-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-1-methyl-6-oxo-2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)-5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 870082-24-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 870082-36-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-1,6-dihydro-1-methyl-6-oxo-5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 870082-37-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 870082-38-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,3-dihydro-3-oxospiro[1H-indene-1,4'-piperidin]-1'-yl)-1,6-dihydro-1-methyl-6-oxo-5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 870082-39-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,3-dihydro-3-oxospiro[1H-indene-1,4'-piperidin]-1'-yl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1026948 CAPLUS  
 DN 143:326377  
 TI Preparation of pyridopyrazinediones and pyrimidopyrazinediones as HIV  
 integrase inhibitors  
 IN Donghi, Monica; Gardelli, Cristina; Jones, Philip; Summa, Vincenzo  
 PA Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Italy  
 SO PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005087766	A1	20050922	WO 2005-GB746	20050301
	W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005221864	A1	20050922	AU 2005-221864	20050301
	CA 2557926	A1	20050922	CA 2005-2557926	20050301
	EP 1725554	A1	20061129	EP 2005-717825	20050301
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2004-551601P	P	20040309		
	WO 2005-GB746	W	20050301		

OS MARPAT 143:326377

AB The invention is directed to pyridopyrazine- and pyrimidopyrazine-dione compds. I [wherein a = single or double bond; G = (un)substituted CH, CH<sub>2</sub>, N or NH; Q = (un)substituted CH or CH<sub>2</sub>; R<sub>5</sub>, R<sub>6</sub> = H, alkyl, etc.; R<sub>7</sub> = substituted alkyl, with some limitations, and pharmaceutically acceptable salts thereof], their synthesis, and their use as inhibitors of HIV integrases and inhibitors of HIV replication. For example, acid II (preparation given) underwent amidation with amine 4-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>OTBS mediated by PyBOP in DCM to give amide III, which was deprotected with HCl in THF followed by cyclization with SOCl<sub>2</sub> in refluxing chloroform to afford IV (R = OBn). Debenzylation of this compound with H<sub>2</sub> in the presence of Pd/C led to IV (R = OH). I and their pharmaceutical compns. are useful for preventing or treating infection by HIV and for preventing, treating or delaying the onset of AIDS.


IT 865301-24-2P 865301-26-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridopyrazinediones and pyrimidopyrazinediones as HIV integrase inhibitors)


RN 865301-24-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[1-[(1,1-dimethylethoxy)carbonyl]methylamino]-3-butenyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 865301-26-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-2-[1-[[[1,1-dimethylethoxy)carbonyl]methylamino]-3-butenyl]-1,6-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RE.CNT 2        THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1011260 CAPLUS  
 DN 143:338973  
 TI Phenyldihydroxypyrimidines as HCV NS5B RNA dependent RNA polymerase inhibitors. Part II: Sulfonamides  
 AU Ponzi, S.; Giuliano, C.; Donghi, M.; Poma, M.; Matassa, V. G.; Stansfield, I.  
 CS Department of Medicinal Chemistry, IRBM/MRL Rome, Rome, 00040, Italy  
 SO Letters in Drug Design & Discovery (2005), 2(6), 456-461  
 CODEN: LDDDAW; ISSN: 1570-1808  
 PB Bentham Science Publishers Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 143:338973  
 AB 5,6-Dihydroxypyrimidine-4-carboxylic acids are a promising series of hepatitis C virus (HCV) NS5B polymerase inhibitors that bind at the active site of the enzyme. Here we report the evolution and SAR of a series of 2-{2-[(arylsulfonyl)amino]phenyl} analogs that show greater than 2 orders of magnitude improved activity over the original lead.  
 IT 865876-03-5P 866052-11-1P 866052-12-2P  
 866052-13-3P 866052-14-4P 866052-15-5P  
 866052-16-6P 866052-17-7P 866052-18-8P  
 866052-19-9P 866052-20-2P 866052-21-3P  
 866052-22-4P 866052-23-5P 866052-24-6P  
 866052-25-7P 866052-26-8P 866052-27-9P  
 866052-28-0P 866052-29-1P 866052-30-4P  
 866052-31-5P 866052-32-6P 866052-33-7P  
 866052-34-8P 866052-35-9P 866052-36-0P  
 866052-37-1P 866052-38-2P 866052-39-3P  
 866052-40-6P 866052-41-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (phenyldihydroxypyrimidines as HCV NS5B RNA dependent RNA polymerase inhibitors)  
 RN 865876-03-5 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-thienylcarbonyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 866052-11-1 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[2-[(2-naphthalenylsulfonyl)amino]-3-[(2-thienylcarbonyl)amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-12-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(phenylsulfonyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 866052-13-3 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 866052-14-4 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[2-[[[2-nitrophenyl)sulfonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)






RN 866052-15-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[2-(chlorophenyl)sulfonyl]methyl]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-16-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 866052-17-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[2-[[[3-nitrophenyl]sulfonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-18-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 866052-19-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[2-[[[4-nitrophenyl]sulfonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-20-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[2-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-21-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[4-ethylphenyl)sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-22-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[2-[[4-methylphenyl)sulfonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-23-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[4-chlorophenyl)sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-24-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[1,1'-biphenyl]-4-ylsulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-25-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[3,4-dichlorophenyl]sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-26-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[2,3-dichlorophenyl]sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-27-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[(3-chloro-2-methylphenyl)sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI)  
(CA INDEX NAME)




RN 866052-28-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[2-[(2-naphthalenylsulfonyl)amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-29-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[2-[(1-naphthalenylsulfonyl)amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 866052-30-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[2,5-dichlorophenyl)sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 866052-31-5 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[2-[[5-chloro-2-methoxyphenyl)sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 866052-32-6 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[2-[[4-amino-3-

chlorophenyl)sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI)  
(CA INDEX NAME)




RN 866052-33-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(1,2,3,4-tetrahydro-6-isoquinolinyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 866052-34-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(2,4,5-trichlorophenyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 866052-35-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[(2,4-dichloro-5-methylphenyl)sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI)  
(CA INDEX NAME)




RN 866052-36-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(2,3,4-trichlorophenyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 866052-37-1 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(2,3,4-trifluorophenyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 866052-38-2 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(2,4,6-trichlorophenyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 866052-39-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(2,4,6-trimethylphenyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 866052-40-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-5-[(2-thienylcarbonyl)amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 866052-41-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[5-chloro-2-[[[(4-chlorophenyl)sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




IT 391680-85-6 866052-06-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(phenyldihydroxypyrimidines as HCV NS5B RNA dependent RNA polymerase inhibitors)


RN 391680-85-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(2-nitrophenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 866052-06-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(5-chloro-2-nitrophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT 391680-86-7P


RL: SPN (Synthetic preparation); PREP (Preparation)

(phenyldihydroxypyrimidines as HCV NS5B RNA dependent RNA polymerase inhibitors)

RN 391680-86-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(2-aminophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/500,971




RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1011259 CAPLUS  
 DN 143:338972  
 TI Phenyldihydroxypyrimidines as HCV NS5B RNA dependent RNA polymerase inhibitors. Part I: Amides and ureas  
 AU Crescenzi, B.; Poma, M.; Ontoria, J. M.; Marchetti, A.; Nizi, E.; Matassa, V. G.; Gardelli, C.  
 CS Department of Chemistry, IRBM, MRL Rome, Rome, 00040, Italy  
 SO Letters in Drug Design & Discovery (2005), 2(6), 451-455  
 CODEN: LDDDAW; ISSN: 1570-1808  
 PB Bentham Science Publishers Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 143:338972  
 AB 2-Phenyl-5,6-dihydroxypyrimidine-4-carboxylic acids were discovered as specific inhibitors of the NS5B polymerase of the Hepatitis C Virus. In-depth structure-activity investigations at the ortho and meta positions of the Ph ring were undertaken, and compds. with greatly improved activity over the original lead have been discovered.  
 IT 391680-76-5P 865876-14-8P 865876-16-0P  
 866006-00-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (phenyldihydroxypyrimidines as HCV NS5B RNA dependent RNA polymerase inhibitors)  
 RN 391680-76-5 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 865876-14-8 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[(phenylmethoxy)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865876-16-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chlorophenyl)methyl]amino]sulfonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 866006-00-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[(1-oxo-3-phenylpropyl)amino]phenyl]- (9CI) (CA INDEX NAME)



IT 572917-17-0P 790661-23-3P 865875-91-8P  
 865875-92-9P 865875-93-0P 865875-94-1P  
 865875-95-2P 865875-96-3P 865875-97-4P  
 865875-98-5P 865875-99-6P 865876-00-2P  
 865876-01-3P 865876-02-4P 865876-03-5P  
 865876-04-6P 865876-05-7P 865876-06-8P  
 865876-07-9P 865876-08-0P 865876-09-1P  
 865876-10-4P 865876-11-5P 865876-12-6P  
 865876-13-7P 865876-15-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(phenyldihydroxypyrimidines as HCV NS5B RNA dependent RNA polymerase inhibitors)


RN 572917-17-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-hydroxyphenyl)-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 790661-23-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-hydroxyphenyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 865875-91-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(phenylamino)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865875-92-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(phenoxy carbonyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865875-93-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-  
[[[(phenylmethyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865875-94-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(cyclohexylamino)carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 865875-95-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[[[(2-methoxyphenyl)methyl]amino]carbonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 865875-96-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[[[(3-methoxyphenyl)methyl]amino]carbonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 865875-97-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[[[(4-methoxyphenyl)methyl]amino]carbonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 865875-98-5 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[[[(3-methylphenyl)methyl]amino]carbonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 865875-99-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[[[(1S)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 865876-00-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[[[(1S)-1-(1-naphthalenyl)ethyl]amino]carbonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865876-01-3 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[[[(1R)-1-(1-naphthalenyl)ethyl]amino]carbonyl]amino]phenyl]-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865876-02-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-(benzoylamino)phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 865876-03-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-thienylcarbonyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865876-04-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2-thienylacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865876-05-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 865876-06-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[(phenylamino)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865876-07-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865876-08-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[(2-phenylethyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865876-09-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[(3-phenylpropyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 865876-10-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(cyclohexylamino)carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 865876-11-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-fluorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 865876-12-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-bromophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 865876-13-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chloro-6-methylphenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 865876-15-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[2-[[[(phenylmethyl)amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




IT 391680-85-6 391680-87-8 865875-88-3  
865875-89-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(phenyldihydroxypyrimidines as HCV NS5B RNA dependent RNA polymerase inhibitors)


RN 391680-85-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(2-nitrophenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-87-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 865875-88-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2-aminophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 865875-89-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2-aminophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

10/500,971



● HCl

RE.CNT 17      THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:696887 CAPLUS  
 DN 143:194107  
 TI Pyrimidyl phosphonate antiviral compounds and methods of use  
 IN Jin, Haolun; Kim, Choung U.  
 PA Gilead Sciences, Inc., USA  
 SO PCT Int. Appl., 170 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070901	A2	20050804	WO 2005-US815	20050111
	WO 2005070901	A3	20060504		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005206511	A1	20050804	AU 2005-206511	20050111
	CA 2552584	A1	20050804	CA 2005-2552584	20050111
	US 2005282839	A1	20051222	US 2005-33422	20050111
	EP 1711476	A2	20061018	EP 2005-705460	20050111
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
PRAI	US 2004-536010P	P	20040112		
	WO 2005-US815	W	20050111		
OS	MARPAT 143:194107				
AB	Pyrimidine I and pyrimidinone II phosphonate compds. R1 = H, F, Cl, Br, I, OH, OR, NH2, ammonium, alkylamino, dialkylamino, trialkylammonium, carboxy, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkyl sulfone, aryl sulfone, aryl sulfoxide, arylthio, sulfonamide, alkyl sulfoxide, formyl, ester, amido, 5-7 membered ring lactone, nitrile, azido, nitro, C1-18 alkyl, C1-18 substituted alkyl, C2-18 alkenyl, C2-C18 substituted alkenyl, C2-18 alkynyl, C2-18 substituted alkynyl, C6-20 aryl, C6-20 substituted aryl, C2-20 substituted heterocycle, and C2-20 substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, etc. R2a, R5 = independently selected from H, carboxy, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkyl sulfone, aryl sulfone, aryl sulfoxide, arylthio, sulfonamide, alkyl sulfoxide, formyl, ester, amido, 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile, azido, nitro, C1-18 alkyl, C1-18 substituted alkyl, C2-18 alkenyl, C2-18 substituted alkenyl, C2-18 alkynyl, C2-18 substituted alkynyl, C6-20 aryl, C6-20 substituted aryl, C2-20 heterocycle, and C2-20 substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, etc.; R2b, R3, R4 = H, OH, OR, amino, ammonium, alkylamino, dialkylamino, trialkylammonium, carboxy, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkyl sulfone, aryl sulfone, aryl sulfoxide, arylthio, sulfonamide, alkyl sulfoxide, formyl, ester, amido,				



5-7 membered ring lactam, 5-7 membered ring lactone, nitrile, azido, nitro, C1-18 alkyl, C1-18 substituted alkyl, C2-18 alkenyl, C2-18 substituted alkenyl, C2-18 alkynyl, C2-18 substituted alkynyl, C6-20 aryl, C6-20 substituted aryl, C2-20 heterocycle, and C2-20 substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, etc.; and methods for viral inhibition are disclosed. The compds. include at least one phosphonate group covalently attached at any site.


IT 518047-36-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidyl phosphonate antiviral compds. and methods of use)

RN 518047-36-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-2-(4-methylphenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 518047-35-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidyl phosphonate antiviral compds. and methods of use)

RN 518047-35-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-(bromomethyl)phenyl]-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:588951 CAPLUS  
 DN 143:115559  
 TI Preparation of hydroxypyrimidinone derivatives as HIV integrase inhibitors  
 IN Mikamiyama, Hidenori; Iwata, Minako; Taoda, Yoshiyuki  
 PA Shionogi & Co., Ltd., Japan  
 SO PCT Int. Appl., 124 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005061490	A1	20050707	WO 2004-JP19048	20041221
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1698628	A1	20060906	EP 2004-807405	20041221
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
PRAI	JP 2003-423947	A	20031222		
	WO 2004-JP19048	W	20041221		

OS MARPAT 143:115559

AB The title compds. I [X represents NR10CO, etc.; R10 represents hydrogen, etc.; Z1 and Z3 each represents a single bond, etc.; Z2 represents a single bond, etc.; Ar represents optionally substituted aryl, etc.; R1 represents lower alkyl, etc., and R2 represents hydrogen, etc., provided that R1 and R2 may together with the adjacent atoms form an optionally substituted heterocycle] are prepared Thus, the title compound II was prepared in a multistep process from 4-bromobenzonitrile. In an assay for integrase inhibiting activity, compds. of this invention showed IC50 values of 1.8 ng/mL to 57 ng/mL. Formulations are given.


IT 857665-06-6P 857665-07-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of hydroxypyrimidinone derivs. as HIV integrase inhibitors)

RN 857665-06-6 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(4-bromophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



10/500,971

RN 857665-07-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(4-bromophenyl)-5,6-dimethoxy-, methyl ester (9CI) (CA INDEX NAME)




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:371047 CAPLUS  
 DN 142:430286  
 TI A synthesis of 5-hydroxy-6-oxo-1,6-dihydropyrimidine derivatives, useful as intermediates in the preparation of pharmacologically active compounds  
 IN Dreher, Spencer D.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 19 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005090668	A1	20050428	US 2004-954752	20040930
PRAI	US 2003-514880P	P	20031028		
OS	CASREACT 142:430286; MARPAT 142:430286				
AB	The invention relates to a preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine derivs. of formula I [wherein: R1 is H, alkoxy, (cyclo)alkyl, or aryl, etc.; R2 is alkyl, aryl, or alkylenearyl, etc.; R3 is alkyl], useful as intermediates in the preparation of pharmacol. active compds. The invention compds. were prepared by condensation of dihydroxyfumarate derivs. with amidines. For instance, 5-hydroxy-6-oxo-1,6-dihydropyrimidine derivative II was prepared via heterocyclization/condensation of fumarate derivative III with cyclopropane-1-carboximidamide with a yield of 92%.				
IT	749886-66-6P 749886-67-7P 749886-68-8P 749886-76-8P 749886-77-9P RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (synthesis of 5-hydroxy-6-oxo-1,6-dihydropyrimidine derivs. useful as intermediates in the preparation of pharmacol. active compds.)				
RN	749886-66-6 CAPLUS				
CN	4-Pyrimidinecarboxylic acid, 1,6-dihydro-6-oxo-5-(phenylmethoxy)-2-(4-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				




RN 749886-67-7 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-2-(3-nitrophenyl)-6-oxo-5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 749886-68-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-2-(4-methoxyphenyl)-6-oxo-5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 749886-76-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-6-oxo-2-phenyl-5-(phenylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 749886-77-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-6-oxo-2-phenyl-5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:964994 CAPLUS  
 DN 141:410945  
 TI Preparation of benzyl pyrimidinecarboxamide derivative as HIV integrase inhibitors  
 IN Naidu, B. Narasimhulu; Walker, Michael A.; Sorenson, Margaret E.  
 PA Bristol-Myers Squibb Company, USA  
 SO PCT Int. Appl., 106 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096128	A2	20041111	WO 2004-US11759	20040416
	WO 2004096128	A3	20050310		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004229892	A1	20041118	US 2004-824917	20040415
	US 7037908	B2	20060502		
PRAI	US 2003-465176P	P	20030424		

OS MARPAT 141:410945

AB Title compds. represented by the formula I and II [wherein A = methylene or 1,1-disubstituted ethylene; R1 = (un)substituted Ph, pyridinyl, dioxolanylphenyl; R2 = H, Me, OH, oxyalkyl; R5 = (un)substituted Ph or heteroaryl; R6 = alkyl; and pharmaceutically acceptable salts or solvates thereof] were prepared as HIV integrase inhibitors. For example, III was given in a multi-step synthesis starting from 2,6-difluorobenzonitrile. The prepared compds. were tested for HIV-integrase inhibition activity with IC50 values of 0.002-2  $\mu$ M. Thus, title compound and their pharmaceutical compns. are useful as HIV integrase inhibitors for the treatment of AIDS or ARC.


IT 791070-88-7P 791070-90-1P 791070-92-3P  
 791070-94-5P 791070-97-8P 791070-99-0P  
 791071-03-9P 791071-06-2P 791071-08-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzyl (aryl)pyrimidinecarboxamide derivative as HIV integrase inhibitors)


RN 791070-88-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2,6-difluorophenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 791070-90-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 791070-92-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 791070-94-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-fluoro-2-(methylsulfonyl)phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 791070-97-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-fluoro-6-[methyl(methylsulfonyl)amino]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 791070-99-0 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(2,6-dimethoxyphenyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 791071-03-9 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)






RN 791071-06-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-[2-(4-morpholinyl)phenyl]-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 791071-08-4 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[2-[(dimethylamino)sulfonyl]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:767281 CAPLUS  
 DN 141:307054  
 TI Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid  
 AU Stansfield, Ian; Avolio, Salvatore; Colarusso, Stefania; Gennari, Nadia; Narjes, Frank; Pacini, Barbara; Ponzi, Simona; Harper, Steven  
 CS Department of Medicinal Chemistry, IRBM/MRL Rome, Rome, 00040, Italy  
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(20), 5085-5088  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 141:307054  
 AB 5,6-Dihydroxypyrimidine-4-carboxylic acids are a promising series of hepatitis C virus (HCV) NS5B polymerase inhibitors that bind at the active site of the enzyme. Here the authors report a simple 2-thienyl substituted analog that shows 10-fold improved activity over the original lead, and which allowed us to further delineate the key elements of the pharmacophore of this class of inhibitor. This work led to the identification of a trifluoromethyl acylsulfonamide group as a viable replacement for the C4 carboxylic acid in this series.  
 IT 391680-79-8P  
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (derivs. of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid as active site inhibitors of HCV NS5B polymerase)  
 RN 391680-79-8 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-(9CI) (CA INDEX NAME)



IT 391680-92-5  
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
 (derivs. of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid as active site inhibitors of HCV NS5B polymerase)  
 RN 391680-92-5 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)




IT 766557-41-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(derivs. of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid as active site inhibitors of HCV NS5B polymerase)

RN 766557-41-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-hydroxy-6-methoxy-2-(2-thienyl)- (9CI) (CA INDEX NAME)




IT 62222-38-2 766557-40-8

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(derivs. of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid as active site inhibitors of HCV NS5B polymerase)


RN 62222-38-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl- (9CI) (CA INDEX NAME)




RN 766557-40-8 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




IT 572916-86-0P  
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (derivs. of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid as active site inhibitors of HCV NS5B polymerase)  
 RN 572916-86-0 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-6-oxo-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)



IT 572916-85-9P 572916-87-1P 849473-04-7P  
 849475-89-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (derivs. of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid as active site inhibitors of HCV NS5B polymerase)  
 RN 572916-85-9 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 572916-87-1 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-1-methyl-6-oxo-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 849473-04-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-hydroxy-6-methoxy-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 849475-89-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:757340 CAPLUS  
 DN 141:395507  
 TI HCV NS5b RNA-Dependent RNA Polymerase Inhibitors: From  
 $\alpha,\gamma$ -Diketoacids to 4,5-Dihydroxypyrimidine- or 3-Methyl-5-  
 hydroxypyrimidinonecarboxylic Acids. Design and Synthesis  
 AU Summa, Vincenzo; Petrocchi, Alessia; Matassa, Victor G.; Taliani, Marina;  
 Laufer, Ralph; De Francesco, Raffaele; Altamura, Sergio; Pace, Paola  
 CS Departments of Medicinal Chemistry and Biochemistry, IRBM-MRL Rome,  
 Pomezia, 00040, Italy  
 SO Journal of Medicinal Chemistry (2004), 47(22), 5336-5339  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 141:395507  
 AB A new class of the HCV NS5b RNA-dependent RNA polymerase inhibitors, the  
 dihydroxypyrimidinecarboxylic acid derivative, was designed from a diketoacid  
 and meconic acid derivative discovered by screening. Mechanism of action and  
 essential moieties required for activity were identified. The  
 corresponding N-methylpyrimidinone was also prepared; both classes are  
 novel, reversible, and selective inhibitors of the HCV NS5b polymerase  
 with improved druglike characteristics.  
 IT 219529-19-8  
 RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological  
 study); RACT (Reactant or reagent)  
 (preparation of 4,5-dihydroxypyrimidine- or 3-methyl-5-  
 hydroxypyrimidinonecarboxylic acids as HCV NS5b RNA-dependent RNA  
 polymerase inhibitors)  
 RN 219529-19-8 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 2-(4-chlorophenyl)-1,6-dihydro-5-hydroxy-6-  
 oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 790661-22-2P 790661-23-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant  
 or reagent)  
 (preparation of 4,5-dihydroxypyrimidine- or 3-methyl-5-  
 hydroxypyrimidinonecarboxylic acids as HCV NS5b RNA-dependent RNA  
 polymerase inhibitors)  
 RN 790661-22-2 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-  
 (phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 790661-23-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-hydroxyphenyl)-6-oxo- (9CI) (CA INDEX NAME)



IT 62222-38-2P 391680-75-4P 790661-24-4P


790661-25-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids as HCV NS5b RNA-dependent RNA polymerase inhibitors)


RN 62222-38-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl- (9CI) (CA INDEX NAME)




RN 391680-75-4 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(4-chlorophenyl)-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 790661-24-4 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 5-hydroxy-2-(3-hydroxyphenyl)-6-methoxy-  
 (9CI) (CA INDEX NAME)



RN 790661-25-5 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 2-(4-chlorophenyl)-1,6-dihydro-5-methoxy-6-  
 oxo- (9CI) (CA INDEX NAME)




IT 572917-09-0P 572917-18-1P 572917-19-2P  
 572917-20-5P 790661-28-8P 790661-30-2P  
 850354-72-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 4,5-dihydroxypyrimidine- or 3-methyl-5-  
 hydroxypyrimidinonecarboxylic acids as HCV NS5b RNA-dependent RNA  
 polymerase inhibitors)  
 RN 572917-09-0 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-6-methoxy-2-[3-[(4-  
 methoxyphenyl)methoxy]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-18-1 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-2-[3-[(4-  
 methoxyphenyl)methoxy]phenyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)






RN 572917-19-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-20-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-2-(3-hydroxyphenyl)-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 790661-28-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 790661-30-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-2-(3-hydroxyphenyl)-6-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 850354-72-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(4-chlorophenyl)-1,6-dihydro-5-methoxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 572917-17-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids as HCV NS5b RNA-dependent RNA polymerase inhibitors)

RN 572917-17-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-hydroxyphenyl)-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RE.CNT 22


THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:716288 CAPLUS  
 DN 141:218924  
 TI Antiviral agents containing nitrogen-containing heteroaromatic compounds  
 IN Fuji, Masahiro; Matsushita, Shihaku; Mikamiyama, Hidenori  
 PA Shionogi and Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 54 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2004244320	A	20040902	JP 2003-32772	20030210
PRAI	JP 2003-32772		20030210		
OS	MARPAT 141:218924				
AB	The invention provides antiviral agents having HIV integrase inhibitory effects, characterized by containing I [G1 = (substituted) N,; G2 = (substituted) C; G3 = (substituted)N, C, O, S; R1 = (substituted) aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycle; V1, V3 = (substituted) alkylene, alkenylene; V2 = (substituted) alkylene, alkenylene, etc.; X = O, S, NH; Y = hydroxy, mercapto, amino; Z = O, S, NH]. A compound II was prepared, and in vitro tested for its HIV integrase inhibitory effect. A capsule containing an active component 250 mg/capsule was also formulated.				
IT	745803-64-9P 745803-68-3P 745803-72-9P 745803-74-1P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of antiviral agents having HIV integrase inhibitory effects containing nitrogen-containing heteroarom. compds.)				
RN	745803-64-9 CAPLUS				
CN	4-Pyrimidinecarboxylic acid, 1,6-dihydro-6-oxo-2-phenyl-5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)				




RN 745803-68-3 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-1-methyl-6-oxo-2-phenyl-5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 745803-72-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 745803-74-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-methoxy-1-methyl-2-(4-methylphenyl)-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:610061 CAPLUS

DN 141:157128

TI A preparation of pyrimidine derivatives, useful as HIV integrase inhibitors

IN Walker, Michael A.; Gulgeze, Hatice Belgin; Naidu, Narasimhulu B.; Sorenson, Margaret E.; Ueda, Yasutsugu; Matiskella, John

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004062613	A2	20040729	WO 2004-US642	20040112
	WO 2004062613	A3	20041104		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	US 2004204498	A1	20041014	US 2004-755642	20040112
	US 7135467	B2	20061114		
PRAI	US 2003-439594P	P	20030113		

OS MARPAT 141:157128

AB The invention relates to a preparation of pyrimidine derivs. of formula R1CH2N(B)R2 [wherein: R1 is (cyclo)alkyl or (alkyl)aryl, etc.; R2 is H, OH, or (un)substituted alkyl, etc.; B is pyrimidine derivative], useful as HIV-integrase inhibitors. The obtained compds. were screened for HIV-integrase inhibition and HIV replication inhibition. For instance, pyrimidine derivative I (HIV-integrase inhibition: IC50 = 0.003-0.1  $\mu$ M) was prepared via amidation of pyrimidinecarboxylate II by 4-fluorobenzylamine with a yield of 84%.


IT 729608-42-8P 729608-43-9P 729608-44-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidine derivs., useful as HIV-integrase inhibitors)


RN 729608-42-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-1-methyl-2-(3-methyl-1H-1,2,4-triazol-1-yl)-6-oxo-5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 729608-43-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-1-methyl-2-(5-methyl-1H-1,2,4-triazol-1-yl)-6-oxo-5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 729608-44-0 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-(3-methyl-1H-1,2,4-triazol-1-yl)-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:561512 CAPLUS  
 DN 141:243495  
 TI Highly selective synthesis of 2-substituted-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid derivatives using a novel protected dihydroxyfumarate  
 AU Dreher, Spencer D.; Ikemoto, Norihiro; Gresham, Venita; Liu, Jinchu; Dormer, Peter G.; Balsells, Jaume; Mathre, David; Novak, Thomas J.; Armstrong, Joseph D.  
 CS Department of Process Research, Merck & Co., Inc., Rahway, NJ, 07065-0900, USA  
 SO Tetrahedron Letters (2004), 45(31), 6023-6025  
 CODEN: TELEAY; ISSN: 0040-4039  
 PB Elsevier  
 DT Journal  
 LA English  
 OS CASREACT 141:243495  
 AB A high yielding (50-96%) route to 2-substituted-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid derivs., e.g. I, has been developed using a rationally designed dihydroxyfumarate derivative. The fully unprotected pyrimidinone heterocycle II was prepared in quant. yield upon treatment of I with HCl.  
 IT 749886-77-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (highly selective synthesis of dihydropyrimidine carboxylic acid derivs. using a novel protected dihydroxyfumarate)  
 RN 749886-77-9 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-6-oxo-2-phenyl-5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 62222-38-2P 749886-66-6P 749886-67-7P  
 749886-68-8P 749886-76-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (highly selective synthesis of dihydropyrimidine carboxylic acid derivs. using a novel protected dihydroxyfumarate)  
 RN 62222-38-2 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl- (9CI) (CA INDEX NAME)




RN 749886-66-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-6-oxo-5-(phenylmethoxy)-2-(4-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 749886-67-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-2-(3-nitrophenyl)-6-oxo-5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 749886-68-8 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-2-(4-methoxyphenyl)-6-oxo-5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 749886-76-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-6-oxo-2-phenyl-5-(phenylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)






IT 62222-36-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(trace product in the highly selective synthesis of dihydropyrimidine  
carboxylic acid derivs. using a novel protected dihydroxyfumarate)

RN 62222-36-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl-, methyl  
ester (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:591157 CAPLUS  
 DN 139:149641  
 TI Preparation of pyrimidinones as viral polymerase inhibitors  
 IN Avolio, Salvatore; Colarusso, Stefania; Conte, Immacolata; Harper, Steven;  
 Koch, Uwe; Malancona, Savina; Matassa, Victor Giulio; Narjes, Frank;  
 Petrocchi, Alessia; Summa, Vincenzo  
 PA Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Italy  
 SO PCT Int. Appl., 82 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Appl PCT*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062211	A1	20030731	WO 2003-GB124	20030115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2473508	A1	20030731	CA 2003-2473508	20030115
	EP 1470113	A1	20041027	EP 2003-700366	20030115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005130997	A1	20050616	US 2003-500971	20030115
	JP 2005524627	T	20050818	JP 2003-562091	20030115
PRAI	GB 2002-1179	A	20020118		
	WO 2003-GB124	W	20030115		

OS MARPAT 139:149641

AB Title compds. I [wherein Z = (un)substituted alkynyl, aryl, or heteroaryl; R1 = (un)substituted alkyl or (aryl)alkyl; R2 = H, (un)substituted alkyl, alkylcarbonyl, aryl, arylcarbonyl, heteroaryl, (aryl)alkyl, (heteroaryl)alkyl; R3 = H, alkyl, (heterocycloalkyl)alkyl, dialkylaminoalkyl, (alkylcarbonyloxy)alkyl, (cycloalkoxycarbonyloxy)alkyl; and their pharmaceutically acceptable salts] were prepared as inhibitors of viral polymerases, especially the hepatitis C virus (HCV) polymerase enzyme. For example, II was prepared from 3-nitrothiophene-2-carbonitrile (preparation given) by base-catalyzed nucleophilic addition of hydroxylamine, reaction with di-Me acetylenedicarboxylate in CH<sub>2</sub>Cl<sub>2</sub>, intramol. cyclocondensation in xylene, room temperature O-acylation with pivaloyl chloride in the presence of 4-DMAP, base-catalyzed N-methylation with di-Me sulfate for 1 h, hydrogenation over Pd/C, and reaction with ortho-chlorobenzyl isocyanate in dichloromethane. I exhibited an IC<sub>50</sub> value of 100  $\mu$ M or less for inhibition of HCV polymerase. Thus, I and their pharmaceutical compns. are useful for treating or preventing an illness due to HCV (no data).

IT 391680-92-5P 391680-96-9P 391681-00-8P  
 572916-82-6P 572916-83-7P 572916-84-8P  
 572916-86-0P 572916-87-1P 572917-06-7P  
 572917-14-7P 572917-15-8P 572917-18-1P  
 572917-19-2P 572917-20-5P 572917-22-7P  
 572917-23-8P 572917-29-4P 572917-30-7P  
 572917-31-8P 572917-32-9P 572917-36-3P


572917-37-4P 572917-39-6P 572917-41-0P  
 572917-43-2P 572917-44-3P 572917-45-4P  
 572917-58-9P 572917-60-3P 572917-61-4P  
 572917-63-6P 572917-65-8P 572917-67-0P  
 572917-74-9P 572917-76-1P 572917-77-2P  
 572917-78-3P 572917-81-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(intermediate; preparation of pyrimidinones as viral polymerase inhibitors)


RN 391680-92-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-,  
 methyl ester (9CI) (CA INDEX NAME)




RN 391680-96-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-nitro-2-thienyl)-6-  
 oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391681-00-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-  
 thienyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572916-82-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-2-  
 (3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572916-83-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-2-(3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572916-84-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-amino-2-thienyl)-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572916-86-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-6-oxo-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 572916-87-1 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-1-methyl-6-oxo-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 572917-06-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-6-oxo-2-[3-[(2E)-3-phenyl-2-propenyl]amino]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 572917-14-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonylamino]-3-thienyl]-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-15-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]-3-thienyl]-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-18-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-19-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-20-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-1,6-dihydro-2-(3-hydroxyphenyl)-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-22-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-2-(3-nitrophenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-23-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-aminophenyl)-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-29-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-(3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 572917-30-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(acetyloxy)-1,6-dihydro-1-methyl-2-(3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 572917-31-8 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(acetyloxy)-2-(3-amino-2-thienyl)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)






RN 572917-32-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(acetyloxy)-1,6-dihydro-1-methyl-6-oxo-2-[3-[(phenylmethyl)sulfonyl]amino]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-36-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-formyl-2-thienyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-37-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-2-(3-formyl-2-thienyl)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-39-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-carboxy-2-thienyl)-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-6-oxo-, 4-methyl ester (9CI) (CA INDEX NAME)




RN 572917-41-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-thienyl]-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 572917-43-2 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(1,1-dimethylethoxy)-2-(3-formyl-2-thienyl)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 572917-44-3 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-(1,1-dimethylethoxy)-1,6-dihydro-1-methyl-6-oxo-2-[3-[(1E)-2-phenylethenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 572917-45-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-(2-phenylethenyl)-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-58-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-2-(2-furanyl)-1,6-dihydro-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 572917-60-3 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-2-(3-formyl-2-furanyl)-1,6-dihydro-1-methyl-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 572917-61-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-6-oxo-2-[3-[(1E)-2-phenylethenyl]-2-furanyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 572917-63-6 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-6-oxo-2-(3-

thienyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 572917-65-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-1-methyl-6-oxo-2-[(trimethylsilyl)ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 572917-67-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1-[2-(2-chlorophenyl)ethyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-74-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-amino-2-thienyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-76-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(1,1-dimethylethoxy)-1,6-dihydro-1-methyl-2-(3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-77-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-amino-2-thienyl)-5-(1,1-dimethylethoxy)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 572917-78-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(1,1-dimethylethoxy)-1,6-dihydro-1-methyl-6-oxo-2-[3-[[[(2-phenyl-4-thiazolyl)methyl]amino]carbonyl]amino]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 572917-81-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)methoxy]carbonyl]amino]-2-thienyl]-5-(1,1-dimethylethoxy)-1,6-dihydro-1-methyl-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 572916-89-3 572917-24-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinones as viral polymerase inhibitors)


RN 572916-89-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 572917-24-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-2-(3-nitrophenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 572916-81-5P 572917-09-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of pyrimidinones as viral polymerase inhibitors)

RN 572916-81-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[(1Z)-4-(2-chlorophenyl)-1-butenyl]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 572917-09-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(benzoyloxy)-6-methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-, methyl ester (9CI) (CA INDEX NAME)






IT 572916-80-4P, 2-[3-[[[(2-Chlorobenzyl)amino]carbonyl]amino]thien-2-yl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid  
 572916-85-9P 572916-88-2P 572916-90-6P  
 572916-91-7P 572916-92-8P 572916-93-9P  
 572916-94-0P 572916-95-1P 572916-96-2P  
 572916-97-3P 572916-98-4P 572916-99-5P  
 572917-00-1P 572917-01-2P 572917-02-3P  
 572917-03-4P 572917-04-5P 572917-05-6P  
 572917-08-9P 572917-13-6P 572917-16-9P  
 572917-17-0P 572917-21-6P 572917-25-0P  
 572917-26-1P 572917-33-0P 572917-34-1P  
 572917-38-5P 572917-40-9P 572917-42-1P  
 572917-46-5P 572917-48-7P 572917-49-8P  
 572917-50-1P 572917-51-2P 572917-53-4P  
 572917-59-0P 572917-62-5P 572917-64-7P  
 572917-66-9P 572917-68-1P 572917-69-2P  
 572917-70-5P 572917-73-8P 572917-75-0P  
 572917-80-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(viral polymerase inhibitor; preparation of pyrimidinones as viral polymerase inhibitors)


RN 572916-80-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572916-85-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 572916-88-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 572916-90-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-(3-nitro-2-thienyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 572916-91-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(3-amino-2-thienyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 572916-92-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-bromo-2-thienyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572916-93-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-(acetamino)-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572916-94-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-(benzoylamino)-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572916-95-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-[3-[(2-methyl-1H-indol-3-yl)acetyl]amino]-2-thienyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 572916-96-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572916-97-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-  
[[ (phenylamino) carbonyl] amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 572916-98-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[1,1'-biphenyl]-2-ylamino)carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-  
(9CI) (CA INDEX NAME)




RN 572916-99-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(diphenylmethyl)amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-00-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-[3-[[[1-(1-naphthalenyl)ethyl]amino]carbonyl]amino]-2-thienyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-01-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-  
[[[(2-phenylcyclopropyl)amino]carbonyl]amino]-2-thienyl]- (9CI) (CA INDEX  
NAME)




RN 572917-02-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-  
[[[(2-phenylethyl)amino]carbonyl]amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 572917-03-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-[[ (2-methylpropoxy) carbonyl] amino]-2-thienyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 572917-04-5 CAPLUS

CN Acetamide, 2-[[[ [1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(3-thienyl)-4-pyrimidinyl] carbonyl] oxy] (phenylmethyl) amino]- (9CI) (CA INDEX NAME)




RN 572917-05-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-[[ (2E)-3-phenyl-2-propenyl] amino]-2-thienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 572917-08-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-2-thienyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 572917-07-8

CMF C19 H19 N3 O4 S




Ph-(CH<sub>2</sub>)<sub>3</sub>-NH

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 572917-13-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-16-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-17-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-hydroxyphenyl)-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-21-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[1,1'-biphenyl]-2-ylamino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI)  
(CA INDEX NAME)




RN 572917-25-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(3-carboxyphenyl)amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-26-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-[[[phenylmethyl]sulfonyl]amino]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 572917-33-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-[3-[(2-naphthalenylsulfonyl)amino]-2-thienyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-34-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-formyl-2-thienyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-38-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-carboxy-2-thienyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 572917-40-9 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 572917-42-1 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-[(1E)-2-phenylethenyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 572917-46-5 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-(2-phenylethyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 572917-48-7 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-[3-[(1E)-4-(2-chlorophenyl)-1-butenyl]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 572917-49-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-(4-phenylbutyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 572917-50-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-1-methyl-6-oxo- (9CI) (CA INDEX NAME)




RN 572917-51-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[(3,4-dichlorophenyl)methoxy]phenyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 572917-53-4 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(2-furanyl)-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)



RN 572917-59-0 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-[(1E)-2-phenylethenyl]-2-furanyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 572917-62-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 572917-64-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)




RN 572917-66-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1-[2-(2-chlorophenyl)ethyl]-1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 572917-68-1 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1-ethyl-1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 572917-69-2 CAPLUS




CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-1-(phenylmethyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 572917-70-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 572917-73-8 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-2-[3-[[[2-(1-naphthalenyl)ethyl]sulfonyl]amino]-2-thienyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 572917-75-0 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-[3-[[[[(2-phenyl-4-thiazolyl)methyl]amino]carbonyl]amino]-2-thienyl]- (9CI)

(CA INDEX NAME)



RN 572917-80-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)methoxy]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo- (9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:334912 CAPLUS  
 DN 138:354001  
 TI Preparation of N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase  
 IN Crescenzi, Benedetta; Gardelli, Cristina; Muraglia, Ester; Nizi, Emanuela; Orvieto, Federica; Pace, Paola; Pescatore, Giovanna; Petrocchi, Alessia; Poma, Marco; Rowley, Michael; Scarpelli, Rita; Summa, Vincenzo  
 PA Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Italy  
 SO PCT Int. Appl., 217 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003035077	A1	20030501	WO 2002-GB4753	20021021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2463976	A1	20030501	CA 2002-2463976	20021021
AU 2002334207	A2	20030506	AU 2002-334207	20021021
EP 1441735	A1	20040804	EP 2002-801950	20021021
EP 1441735	B1	20060222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013522	A	20040908	BR 2002-13522	20021021
HU 200401740	A2	20041228	HU 2004-1740	20021021
JP 2005511543	T	20050428	JP 2003-537644	20021021
CN 1700918	A	20051123	CN 2002-825765	20021021
NZ 533057	A	20051125	NZ 2002-533057	20021021
AT 318140	T	20060315	AT 2002-801950	20021021
PT 1441735	T	20060630	PT 2002-801950	20021021
ES 2258668	T3	20060901	ES 2002-2801950	20021021
ZA 2004002796	A	20050120	ZA 2004-2796	20040413
US 2005025774	A1	20050203	US 2004-493280	20040420
NO 2004002165	A	20040525	NO 2004-2165	20040525
US 2006258860	A1	20061116	US 2006-491815	20060724
PRAI US 2001-339568P	P	20011026		
US 2002-362191P	P	20020306		
WO 2002-GB4753	W	20021021		
US 2004-493280	A3	20040420		

OS MARPAT 138:354001

AB Title compds. I [R1 = H, alkyl, etc.; R2 = alkyl; R3 = H, alkyl; R4 = H, alkyl, alkynyl, etc.] are prepared For instance, 5-[(2,2-dimethylpropanoyl)oxy]-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxylate (general procedures provided for preparation) is reacted with 4-fluorobenzylamine (DMF, 90°, 2 h) to yield II. I are inhibitors of HIV integrase and inhibitors of HIV replication and are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. I can be employed

in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


IT 518047-36-4, Methyl 5-[(2,2-dimethylpropanoyl)oxy]-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxylate

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase)

RN 518047-36-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-2-(4-methylphenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT 518047-24-0P, Benzyl 2-[5-(benzoyloxy)-4-(methoxycarbonyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]indoline-1-carboxylate


518047-35-3P, Methyl 2-[4-(bromomethyl)phenyl]-5-[(2,2-dimethylpropanoyl)oxy]-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase)


RN 518047-24-0 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[5-(benzoyloxy)-1,6-dihydro-4-(methoxycarbonyl)-1-methyl-6-oxo-2-pyrimidinyl]-2,3-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 518047-35-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-(bromomethyl)phenyl]-5-(2,2-dimethyl-1-oxopropoxy)-1,6-dihydro-1-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:334911 CAPLUS  
 DN 138:354000  
 TI Preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase  
 IN Di Francesco, Maria Emilia; Gardelli, Cristina; Harper, Steven; Matassa,  
 Victor Giulio; Muraglia, Ester; Nizi, Emanuela; Pace, Paola; Pacini,  
 Barbara; Petrocchi, Alessia; Poma, Marco; Summa, Vincenzo  
 PA Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Italy  
 SO PCT Int. Appl., 315 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035076	A1	20030501	WO 2002-GB4742	20021021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463975	A1	20030501	CA 2002-2463975	20021021
	EP 1441734	A1	20040804	EP 2002-801949	20021021
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005510500	T	20050421	JP 2003-537643	20021021
	US 2005075356	A1	20050407	US 2004-493279	20040420
PRAI	US 2001-348195P	P	20011026		
	WO 2002-GB4742	W	20021021		

OS MARPAT 138:354000

AB The title 4,5-dihydroxypyrimidine-6-carboxamides [I; R1 = H, alkyl, haloalkyl, alkoxy, etc.; R2 = H, alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = H, alkyl; R4 = H, alkyl, haloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared. Thus, refluxing N-hydroxythiophene-2-carboximidamide with di-Me acetylenedicarboxylate in CHCl<sub>3</sub> followed by reacting the resulting Me 5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylate with 4-fluorobenzylamine in DMF afforded I [R1 = 2-thienyl; R2 = H; R3 = 4-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>; R4 = H]. The compds. I are employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


IT 519032-06-5 519032-14-5 519032-15-6  
 519032-16-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase)

RN 519032-06-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(4-methylphenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 519032-14-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(4-amino-3-thienyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 391681-01-9


CMF C10 H9 N3 O4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 519032-15-6 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[1,4-dihydro-5-hydroxy-6-(methoxycarbonyl)-4-oxo-2-pyrimidinyl]-2,3-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 519032-16-7 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[5-(benzoyloxy)-1,4-dihydro-6-(methoxycarbonyl)-4-oxo-2-pyrimidinyl]-3,4-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 391680-92-5P 519031-78-8P 519031-79-9P  
519032-05-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase)

RN 391680-92-5 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 519031-78-8 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 5,6-bis(benzoyloxy)-2-(4-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)






RN 519031-79-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5,6-bis(benzoyloxy)-2-[4-(bromomethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 519032-05-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-[[[(2-chlorophenyl)sulfonyl]amino]carbo-nyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:72061 CAPLUS

DN 136:118465

TI Preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors

IN Gardelli, Cristina; Giuliano, Claudio; Harper, Steven; Koch, Uwe; Narjes, Frank; Ontoria Ontoria, Jesus Maria; Poma, Marco; Ponzi, Simona; Stansfield, Ian; Summa, Vincenzo

PA Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Italy

SO PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002006246	A1	20020124	WO 2001-EP7955	20010711
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2418288	A1	20020124	CA 2001-2418288	20010711
	EP 1309566	A1	20030514	EP 2001-951664	20010711
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004504304	T	20040212	JP 2002-512150	20010711
	US 2004106627	A1	20040603	US 2003-333431	20030709
	US 7091209	B2	20060815		
PRAI	GB 2000-17676	A	20000719		
	WO 2001-EP7955	W	20010711		

OS MARPAT 136:118465

AB RR1 (R1 = 4-carboxy-5,6-dihydroxy-2-pyrimidinyl)[I; R = (un)substituted (hetero)aryl] were prepared Thus, 2-(O2N)C6H4C(:NOH)NH2 (preparation given) N-was alkenylated by MeO2CC.tplbond.CCO2Me and the product cyclized to give, after reduction, N-acylation, and saponification, I [R = 2-(2-ClC6H4CH2NHCONH)C6H4]. Data for biol. activity of I were given.

IT 391680-75-4P 391680-76-5P 391680-77-6P

391680-78-7P 391680-79-8P 391680-80-1P


391680-81-2P 391680-82-3P 391680-83-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors)


RN 391680-75-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(4-chlorophenyl)-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 391680-76-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 391680-77-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(diphenylmethyl)amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 391680-78-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(2,4,6-trichlorophenyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 391680-79-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-  
(9CI) (CA INDEX NAME)




RN 391680-80-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[3-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-2-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)




RN 391680-81-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-6-oxo- (9CI) (CA INDEX NAME)



RN 391680-82-3 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[4-[[[(1-naphthalenylsulfonyl)amino]carbonyl]amino]-3-thienyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 391680-83-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(1E)-2-phenylethenyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 219529-19-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors)

RN 219529-19-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(4-chlorophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 391680-85-6P 391680-86-7P 391680-87-8P  
 391680-88-9P 391680-89-0P 391680-92-5P  
 391680-96-9P 391680-97-0P 391681-00-8P  
 391681-02-0P 391681-04-2P 391681-09-7P  
 391681-10-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-aryldihydroxypyrimidine-4-carboxylic acids as hepatitis C viral polymerase inhibitors)


RN 391680-85-6 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(2-nitrophenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-86-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(2-aminophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-87-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[2-[[[(2-chlorophenyl)methyl]amino]carbonyl]amino]phenyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-88-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-nitrophenyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-89-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-aminophenyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-92-5 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-96-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-(3-nitro-2-thienyl)-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 391680-97-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-amino-2-thienyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 391681-00-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]-3-thienyl]-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 391681-02-0 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 2-(4-amino-3-thienyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 391681-01-9

CMF C10 H9 N3 O4 S






CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 391681-04-2 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-2-[4-[[[(1-naphthalenylsulfonyl)amino]carbonyl]amino]-3-thienyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 391681-09-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(3-formyl-2-thienyl)-1,6-dihydro-5-hydroxy-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


10/500,971



RN 391681-10-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-[3-[(1E)-2-phenylethenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1992:571466 CAPLUS  
 DN 117:171466  
 TI Preparation of 2-phenylpyrimidines as agrochemical fungicides  
 IN Minn, Klemens; Braun, Peter; Sachse, Burkhard; Wicke, Heinrich  
 PA Hoechst A.-G., Germany  
 SO Ger. Offen., 48 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4029654	A1	19920402	DE 1990-4029654	19900919
	ZA 9107429	A	19920527	ZA 1991-7429	19910918
	WO 9205159	A1	19920402	WO 1991-EP1790	19910919

W: BR, CA, CS, FI, NO, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE

PRAI DE 1990-4029654 A 19900919

OS MARPAT 117:171466


AB Title compds. I [R1 - R3 = H, halo, H2N, O2N, cyano, thiocyanato, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylamino, C1-4 dialkylamino, halo-C1-4-alkyl, C3-9 cycloalkyl, C1-4 alkylcarbonyl, (substituted) Ph, (substituted) PhO, etc.; R1, R2 and(or) R3 = carbocyclyl, heterocyclyl, etc.; R4 = H, halo, C1-4 alkyl, hydroxy-C1-4-alkyl, C1-4 alkoxy-C1-4-alkyl, (substituted) Ph, (substituted) PhO, (substituted) heterocyclyl, etc.; R5 = halo, C1-9 alkoxy, C2-6 alkynyl, C3-9 cycloalkyl, etc.; R6 = H, halo, hydroxy-C1-4-alkyl, halo-C1-4-alkylthio, C3-9 cycloalkyl, C3-9 heterocyclylalkyl, C1-4 alkoxy-carbonyl, Ph-C1-4-alkyl, etc.; R5R6 = carbocyclyl, heterocyclyl; X = O, S, HN, etc.; Y = O, HN, C1-4-alkylamino, absent when X = O or HN, etc.; n = 0-8] and salts thereof, are prepared To NaH in THF was added dropwise a mixture of HCO2Et and MeOCH2CO2Me to give, after workup, 5-methoxy-2-phenyl-4(1H)pyrimidinone which was treated with POCl3 and PhNMe2 to give 4-chloro-5-methoxy-2-phenylpyrimidine, which was treated with NaH followed by HC.tplbond.CCH2OH to give I (R1-R4, R6 = H; R5 = MeO; X = O, n = 1) (II). In a test against Pseudocercospora herpotrichoides, II at 60 ppm gave 100% control.

IT 142676-15-1P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as agrochem. fungicide)


RN 142676-15-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-phenyl-5,6-bis(2-propynyloxy)-, methyl ester (9CI) (CA INDEX NAME)




8


L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1980:146708 CAPLUS  
 DN 92:146708  
 TI Synthesis of methyl 5,6-dihydroxy-2-phenyl-4-pyrimidinecarboxylate: a corrected structure  
 AU Culbertson, Townley P.  
 CS Pharm. Res. Div., Warner-Lambert/Parke-Davis, Ann Arbor, MI, 48105, USA  
 SO Journal of Heterocyclic Chemistry (1979), 16(7), 1423-4  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 OS CASREACT 92:146708  
 AB Pyrolysis of the adduct of H<sub>2</sub>NCPh:NOH and MeO<sub>2</sub>CC.tplbond.CCO<sub>2</sub>Me leads to Me 5,6-dihydroxy-2-phenyl-4-pyrimidinecarboxylate rather than Me 4,5-dihydro- $\alpha$ ,4-dioxo-2-phenyl-1H-imidazole-5-acetate.  
 IT 62222-38-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and decarboxylation of)  
 RN 62222-38-2 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl- (9CI)  
 (CA INDEX NAME)



IT 73216-83-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and esterification of)  
 RN 73216-83-8 CAPLUS  
 CN 4(1H)-Pyrimidinone, 5-hydroxy-6-[(1H-imidazol-1-yloxy)carbonyl]-2-phenyl- (9CI)  
 (CA INDEX NAME)



IT 62222-36-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and pyrolysis of)  
 RN 62222-36-0 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl-, methyl ester (9CI)  
 (CA INDEX NAME)




IT 73216-84-9P 73216-86-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 73216-84-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5,6-dimethoxy-2-phenyl-, methyl ester (9CI)  
(CA INDEX NAME)




RN 73216-86-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-methoxy-1-methyl-6-oxo-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)




*Previous*


L4 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1979:420462 CAPLUS  
DN 91:20462  
TI Synthesis of 1,2,4-oxadiazines and their rearrangement to pyrimidines  
AU Santilli, Arthur A.; Scotese, Anthony C.  
CS Res. Dev. Div., Wyeth Lab., Inc., Radnor, PA, 19087, USA  
SO Journal of Heterocyclic Chemistry (1979), 16(2), 213-16  
CODEN: JHTCAD; ISSN: 0022-152X  
DT Journal  
LA English  
OS CASREACT 91:20462  
AB Several amide oximes underwent condensation reactions with MeO2CC.tplbond.CCO2Me to give 1:1 adducts. Under basic conditions, these adducts underwent ring closure to give several Me [3-(substituted)-4,5-dihydro-5-oxo-6H-1,2,4-oxadiazin-6-ylidene]acetates, e.g. I. The reactions of these compds. with a variety of amines resulted in addition-rearrangement reactions with the formation of the corresponding Me 2-substituted-5-substituted amino-1,6-dihydro-6-oxo-4-pyrimidinecarboxylates.  
IT 70274-25-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and hydrolysis of)  
RN 70274-25-8 CAPLUS  
CN 4-Pyrimidinecarboxylic acid, 2-(4-chlorophenyl)-1,4,5,6-tetrahydro-5,6-dioxo-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1977:139931 CAPLUS  
 DN 86:139931  
 TI Photodehydrocyclization of 1-styrylimidazoles; an HMO study  
 AU Copper, Geoffrey; Irwin, William J.  
 CS Dep. Pharm., Univ. Aston, Birmingham, UK  
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and  
 Bio-Organic Chemistry (1972-1999) (1976), (19), 2038-45  
 CODEN: JCPRB4; ISSN: 0300-922X  
 DT Journal  
 LA English  
 AB Photodehydrocyclization of 4,5-diphenyl-1-styrylimidazole gave the  
 phenanthroimidazoisoquinoline I via the phenanthroimidazole II. Synthesis  
 and photocyclization of the imidazoisoquinoline III, another possible  
 intermediate, and HMO calcs., especially the resulting localization energies,  
 support the intermediacy of II.  
 IT 62222-38-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and acetylation of)  
 RN 62222-38-2 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl- (9CI)  
 (CA INDEX NAME)



IT 62222-36-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and saponification of)  
 RN 62222-36-0 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 1,6-dihydro-5-hydroxy-6-oxo-2-phenyl-, methyl  
 ester (9CI) (CA INDEX NAME)



=&gt; =&gt; d his

(FILE 'HOME' ENTERED AT 14:20:11 ON 05 JAN 2007)

FILE 'REGISTRY' ENTERED AT 14:20:18 ON 05 JAN 2007

L1.               STRUCTURE UPLOADED  
 L2               13 S L1 SSS SAM  
 L3               305 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 14:22:42 ON 05 JAN 2007

L4               24 S L3

FILE 'CAOLD' ENTERED AT 14:23:26 ON 05 JAN 2007

=&gt; s l3

L5               0 L3

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE  
 ENTRY

TOTAL  
 SESSION

FULL ESTIMATED COST

0.45      301.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
 ENTRY

TOTAL  
 SESSION

CA SUBSCRIBER PRICE

0.00      -18.72

STN INTERNATIONAL LOGOFF AT 14:23:38 ON 05 JAN 2007